VigiPallia : Résultats

CHIMIOTHERAPIE

0 sélectionnée(s) / 327 réponse(s)

(1) 2 3 4 ... 17 > »

Reasons for chemotherapy discontinuation and end-of-life in patients with gastrointestinal cancer - a multicenter prospective AGEO study

PALMIERI, Lola-Jade ; DUBREUIL, Olivier ; BACHET, Jean-Baptiste ; TROUILLOUD, Isabelle ; LOCHER, Christophe ; CORIAT, Romain ; MORYOUSSEF, Frederick ; LANDI, Bruno ; PERKINS, Géraldine ; HAUTEFEUILLE, Vincent ; DOAT, Solène
Clinics and research in hepatology and gastroenterology, 11/05/2020, p. 1-8

Document en ligne

Trends in provision of palliative radiotherapy and chemotherapy among hospices in the United States, 2011-2018

HSU, Sylvia H. ; WANG, Shi-Yi
JAMA oncology, 30/04/2020, Pagination inconnue

Document en ligne

Experiences and hidden needs of older patients, their families and their physicians in palliative chemotherapy decision-making - a qualitative study

TSUBOI, Rie ; SUGISHITA, Mihoko ; HIRAKAWA, Yoshihisa ; ANDO, Yuichi
Japanese journal of clinical oncology, 13/04/2020, Pagination inconnue

Document en ligne

Multicomponent compression bandaging combined with diuretic therapy of anasarca secondary to palliative chemotherapy - a case report

GRADALSKI, Tomasz
JOURNAL OF PALLIATIVE MEDICINE, 16/03/2020, Pagination inconnue

Document en ligne

The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy - a single-institution retrospective review

MOUSA, Luay ; STEPHENS, Julie A. ; BERGER, Michael ; RAMASWAMY, Bhuvaneswari ; LUSTBERG, Maryam ; SARDESAI, Sagar ; WILLIAMS, Nicole ; VANDEUSEN, Jeffrey ; STOVER, Daniel ; CHERIAN, Mathew ; MORGAN, Evan ; WESOLOWSKI, Robert
Supportive care in cancer, 17/03/2020, Pagination inconnue

Document en ligne

Opportunity costs of receiving palliative chemotherapy for metastatic pancreatic ductal adenocarcinoma

BANGE, Erin M. ; DOUCETTE, Abigail ; GABRIEL, Peter E. ; PORTERFIELD, Florence ; HARRIGAN, James J. ; WANG, Robin ; WOJCIESZYNSKI, Andrzej P. ; BOURSI, Ben ; MOONEY, Bethany I. ; REISS, Kim A. ; MAMTANI, Ronac
JCO oncology practice, 04/03/2020, Pagination inconnue

Document en ligne

Combination versus single-agent as palliative chemotherapy for gastric cancer

CHOI, Jin-Hyuk ; CHOI, Yong Won ; KANG, Seok Yun ; JEONG, Geum Sook ; LEE, Hyun Woo ; JEONG, Seong Hyun ; PARK, Joon Seong ; AHN, Mi Sun ; SHEEN, Seung Soo
BMC Cancer, 02/03/2020, vol.20, n°1, p. 1-10

Document en ligne

Polypharmacy, inappropriate medication use, and drug interactions in older Korean patients with cancer receiving first-line palliative chemotherapy

HONG, Soojung ; LEE, Ju Hyun ; CHUN, Eun Kyeong ; KIM, Kwang-Il ; KIM, Jin Won ; KIM, Se Hyun ; LEE, Yun-Gyoo ; HWANG, In Gyu ; KIM, Jin Young ; KOH, Su-Jin ; KO, Yoon Ho ; SHIN, Seong Hoon ; WOO, In Sook ; KIM, Tae-Yong ; BAEK, Ji Yeon ; KIM, Hyun Jung ; KIM, Hyo Jung ; LEE, Myung Ah ; KWON, Jung Hye ; HONG, Yong Sang ; RYOO, Hun-Mo ; KIM, Jee Hyun
The oncologist, 03/2020, vol.25, n°3, p. e502-e511

Document en ligne

Successful treatment of unresectable advanced rectal cancer with liver metastases by hemostasis re-irradiation of the rectal cancer and palliative low-dose whole-liver radiation therapy - a case report

YASUDA, Takeshi ; TANAKA, Osamu ; HAYASHI, Sadanari ; NAKAHATA, Yuki ; YASUDA, Yuriko ; OMATSU, Tatsushi ; OBORA, Akihiro ; KOJIMA, Takao ; MATSUO, Masayuki ; YAGI, Nobuaki
Clinical journal of gastroenterology, 02/2020, vol.13, n°1, p. 11-16

Document en ligne

Pressurized intraperitoneal aerosol chemotherapy, a palliative treatment approach for patients with peritoneal carcinomatosis - description of method and systematic review of literature

WINKLER, Carl S. ; SANDHU, Jaspreet ; PETTKE, Erica ; MERCHEA, Amit ; FONG, Yuman ; KUMARA, H. M. C. Shantha ; WHELAN, Richard L.
Diseases of the colon and rectum, 02/2020, vol.63, n°2, p. 242-255

Document en ligne

Utilization and efficacy of palliative chemotherapy for locally advanced or metastatic gastroesophageal carcinoma

BAUMGARTNER, Ruth ; TAGHIZADEH, Hossein ; JOMRICH, Gerd ; SCHOPPMANN, Sebastian Friedrich ; PREUSSER, Matthias ; ILHAN-MUTLU, Aysegul
Anticancer research, 02/2020, vol.40, n°2, p. 965-975

Document en ligne

Experiences of spouses of patients with cancer from the notification of palliative chemotherapy discontinuation to bereavement - a qualitative study in Japan

HISAMATSU, Misako ; SHINCHI, Hiroyuki ; TSUTSUMI, Yumiko
European journal of oncology nursing, 04/2020, vol.45, Pagination inconnue

Document en ligne

Anticancer therapy within the last 30 days of life - results of an audit and re-audit cycle from an Australian regional cancer centre

NGUYEN, Mike ; NG YING KIN, Sean ; SHUM, Evonne ; WANN, Alysson ; TAMJID, Babak ; SAHU, Arvind ; TORRES, Javier
BMC palliative care, 27/01/2020, vol.19, n°1, p. 1-10

Document en ligne

Chemotherapy near the end of life in onco-hematological adult patients

SANCHEZ-CUERVO, Marina ; GARCIA-BASAS, Lorena ; GOMEZ DE SALAZAR-LOPEZ DE SILANES, Esther ; PUEYO-LOPEZ, Cristina ; BERMEJO-VICEDO, Teresa
The American journal of hospice and palliative care, 23/01/2020, Pagination inconnue

Document en ligne

Comparative effectiveness of palliative chemotherapy in metastatic breast cancer - a real-world evidence analysis

FEINBERG, Bruce ; KISH, Jonathan ; DOKUBO, Igoni ; WOJTYNEK, Jeff ; GAJRA, Ajeet ; LORD, Kevin
The oncologist, 17/01/2020, p. 1-8

Document en ligne

Thème : Médecine. Cote : eD03.05.01

CHIMIOTHERAPIE ; CANCER SEIN ; EFFICACITE

BACKGROUND: In the absence of randomized controlled trials, real-world evidence may aid practitioners in optimizing the selection of therapy for patients with cancer. The study's aim was to determine real-word use, as well as compare effectiveness, of single-agent and combination chemotherapy as palliative treatment for female patients with metastatic breast cancer (mBC).
MATERIALS AND METHODS: Using administrative claims data from the Symphony Health's Integrated Oncology Dataverse, female patients with mBC treated with at least one chemotherapy-only treatment (COT) between January 1, 2013, and December 31, 2017 were selected. The frequency of use of single-agent versus combination chemotherapy overall and by line of therapy (LOT) was calculated whereas effectiveness was measured using time to next treatment (TNT).
RESULTS: A total of 12,381 patients with mBC were identified, and 3,777 (31%) received at least one line of COT. Of the 5,586 observed LOTs among the 3,777 patients, 66.5% were single-agent and 33.5% combination chemotherapy. Combination chemotherapy was most frequently used in first-line (45%) and least frequently in fifth-line (16%). Across all LOTs, median TNT was significantly longer for single-agent versus combination chemotherapy (5.3 months vs. 4.1 months, p < .0001). Comparison of median TNT by LOT showed significance in third-line and greater but not in first-line or second-line. Among single agents, the median TNT for patients receiving capecitabine was longest in comparison to all other single agents.
CONCLUSIONS: The frequency of combination COT use, particularly in first-line, warrants further research given published guideline recommendations. The observed TNT difference favoring single-agent treatment in later lines supports guideline recommendations. Variance between single-agent preference and observed TNT was noteworthy.
IMPLICATIONS FOR PRACTICE: Although published data from evidence- and consensus-based guidelines recommend single-agent over combination chemotherapy, the extensive list of agents available for use and a gap in the comparative effectiveness research of these agents have resulted in significant variances in patterns of care. The aim of this study was to assess real-world treatment patterns and their effectiveness during palliative therapy of metastatic breast cancer. The objective was to understand when and how chemotherapy-only treatment is used in metastatic breast cancer and whether comparative effectiveness analysis supports the observed patterns of care.

Origine : PubMed

Anti-epidermal growth factor receptor monoclonal antibody plus palliative chemotherapy as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma

CHEN, Chen ; ZHOU, Yixin ; ZHANG, Xuanye ; FU, Sha ; LIN, Zuan ; FANG, Wenfeng ; YANG, Yunpeng ; HUANG, Yan ; ZHAO, Hongyun ; HONG, Shaodong ; ZHANG, Li
Cancer medicine, 19/01/2020, p. 1-12

Document en ligne

Thème : Médecine. Cote : eD03.05

CHIMIOTHERAPIE ; CANCER OTO RHINO LARYNGOLOGIQUE ; THERAPEUTIQUE ANTI CANCEREUSE ; CHINE

Background: Platinum-based chemotherapy is the standard of care as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (RM-NPC); however, the prognosis of patients with RM-NPC remains poor. The aim of this study was to evaluate the role of anti-epidermal growth factor receptor (anti-EGFR) antibody plus chemotherapy for RM-NPC.
Methods: RM-NPC patients who received first-line chemotherapy plus an anti-EGFR antibody were recruited from Sun Yat-Sen University Cancer Center between July 2007 and November 2017. Survival analyses were performed using the Kaplan-Meier method with a log-rank test. A Cox proportional hazards model was used for the multivariate analyses.
Results: A total of 203 patients were enrolled in the present study. The median follow-up time was 34.3 months (interquartile range: 19.7-66.5 months). The median progression-free survival (PFS) was 8.9 months (95% CI: 7.7-10.0 months) and the median overall survival (OS) was 29.1 months (95% CI: 23.5-34.6 months). The 1-, 3-, and 5-year PFS and OS rates were 35.5% and 79.6%, 15.2% and 42.5%, and 11.6% and 23.6%, respectively. The objective response rate (ORR) was 67.5% and the disease control rate (DCR) was 91.1%. The multivariate analysis identified the following prognostic factors for PFS: anti-EGFR agent (P = .010), recurrence/metastasis sequence (P = .016), KPS (P = .017), and combined chemotherapy regimen (P = .015). Independent risk factors for OS included age >43 years (P = .002), Karnofsky performance score =80 (P < .001), and higher level of baseline Epstein-Barr virus (EBV) DNA (P = .008). Leukopenia was the most common adverse event (AE) in this cohort (any grade, 84.2%; grades 3-4, 43.4%).
Conclusions: Anti-EGFR antibody plus chemotherapy achieved promising antitumor activity with a tolerable toxicity profile in RM-NPC. Thus, randomized clinical trials are warranted to compare the efficacy of chemotherapy with or without anti-EGFR antibody in these patients.

Origine : PubMed

Surrogate decision making of chemotherapy consent - do we really provide informed consent of chemotherapy for patients?

KWON, Jung Hye ; BAEK, Sun Kyung ; KIM, Bong-Seog ; KOH, Su-Jin ; AHN, Hee Kyung ; LIM, Joo Han ; LIM, Chiyeon ; KIM, Do Yeun
The Korean journal of internal medicine, 05/2019, vol.34, n°3, p. 626-633

Document en ligne

Palliative chemotherapy with or without cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck - Indian tertiary care retrospective analysis

BAHL, Ankur ; BHATIA, Komal ; CHOUDHARY, Pragati ; SINGHLA, Suhas ; SHRIVASTAVA, Gunjan ; BAL, Jaspriya ; ANAND, Anil K. ; CHATURVEDI, Harit ; DUA, Bharat
Head and neck, 08/01/2020, Pagination inconnue

Document en ligne

Clinical trial participation and aggressive care at the end of life in patients with ovarian cancer

NITECKI, Roni ; BERCOW, Alexandra S. ; GOCKLEY, Allison A. ; LEE, Hang ; PENSON, Richard T. ; GROWDON, Whitfield B.
International journal of gynecological cancer, 06/01/2020, Pagination inconnue

Document en ligne

Palliative chemotherapy in head and neck cancer - balancing between beneficial and adverse effects

RAJENDRA, Akhil ; NORONHA, Vanita ; JOSHI, Amit ; PATIL, Vijay Maruti ; MENON, Nandini ; PRABHASH, Kumar
Expert review of anticancer therapy, 03/01/2020, p. 1-13

Document en ligne

(1) 2 3 4 ... 17 > »

Actions

##titre_notice##